[go: up one dir, main page]

CY1119399T1 - Aντι-dkk-1 αντισωματα - Google Patents

Aντι-dkk-1 αντισωματα

Info

Publication number
CY1119399T1
CY1119399T1 CY20171101022T CY171101022T CY1119399T1 CY 1119399 T1 CY1119399 T1 CY 1119399T1 CY 20171101022 T CY20171101022 T CY 20171101022T CY 171101022 T CY171101022 T CY 171101022T CY 1119399 T1 CY1119399 T1 CY 1119399T1
Authority
CY
Cyprus
Prior art keywords
dkk
antibodies
human
antigen
bind
Prior art date
Application number
CY20171101022T
Other languages
English (en)
Inventor
Marcio Chedid
Ryan James Darling
Rachelle Jeanette Galvin
Barbara Anne Swanson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1119399T1 publication Critical patent/CY1119399T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση παρέχει ανθρώπινα τροποποιημένα αντισώματα, θραύσματα δεσμεύσεως αντιγόνου αυτών, τα οποία συνδέονται με την ανθρώπινη DKK-1, και αναστέλλουν τη λειτουργία αυτής, και τα οποία είναι αποτελεσματικά για την αγωγή νόσων στις οποίες η παθογένεια διαμεσολαβείται από την DKK-1.
CY20171101022T 2009-04-10 2017-09-29 Aντι-dkk-1 αντισωματα CY1119399T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10
PCT/US2010/030039 WO2010117980A1 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies

Publications (1)

Publication Number Publication Date
CY1119399T1 true CY1119399T1 (el) 2018-02-14

Family

ID=42199718

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20171101022T CY1119399T1 (el) 2009-04-10 2017-09-29 Aντι-dkk-1 αντισωματα
CY20191100531T CY1121637T1 (el) 2009-04-10 2019-05-17 Αντι-dkk-1 αντισωματα
CY20211100700T CY1124412T1 (el) 2009-04-10 2021-08-06 Aνti-dkk-1 αντισωματα

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20191100531T CY1121637T1 (el) 2009-04-10 2019-05-17 Αντι-dkk-1 αντισωματα
CY20211100700T CY1124412T1 (el) 2009-04-10 2021-08-06 Aνti-dkk-1 αντισωματα

Country Status (30)

Country Link
US (1) US8148498B2 (el)
EP (3) EP2417158B9 (el)
JP (1) JP5759977B2 (el)
KR (3) KR20110124364A (el)
CN (1) CN102388065B (el)
AR (1) AR075989A1 (el)
AU (1) AU2010234611B2 (el)
BR (1) BRPI1014157B1 (el)
CA (1) CA2758252C (el)
CY (3) CY1119399T1 (el)
DK (3) DK2417158T4 (el)
EA (1) EA021401B1 (el)
ES (3) ES2728911T3 (el)
HR (3) HRP20171400T1 (el)
HU (3) HUE055376T2 (el)
IL (1) IL214845A (el)
LT (3) LT3514173T (el)
ME (2) ME02798B (el)
MX (1) MX2011010707A (el)
NZ (1) NZ595011A (el)
PL (3) PL2930184T3 (el)
PT (3) PT2417158T (el)
RS (3) RS58612B1 (el)
SG (1) SG175244A1 (el)
SI (3) SI2930184T1 (el)
TR (1) TR201907261T4 (el)
TW (1) TWI546079B (el)
UA (1) UA103916C2 (el)
WO (1) WO2010117980A1 (el)
ZA (1) ZA201107256B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2548817C2 (ru) * 2009-05-12 2015-04-20 Пфайзер Инк. БЛОКИРУЮЩИЕ АНТИТЕЛА ПРОТИВ Dkk-1 И ИХ ПРИМЕНЕНИЯ
ES2780398T3 (es) 2012-12-10 2020-08-25 Biogen Ma Inc Anticuerpo anti-antígeno 2 de células dendríticas sanguíneas y uso de los mismos
WO2016186957A1 (en) 2015-05-18 2016-11-24 Eli Lilly And Company Anti-dkk-1-anti-rankl bispecific antibody compounds
EP3341411A1 (en) * 2015-08-28 2018-07-04 Alector LLC Anti-siglec-7 antibodies and methods of use thereof
LT3370768T (lt) * 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
MA46673A (fr) * 2016-10-26 2019-09-04 Leap Therapeutics Inc Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.
JP2021532085A (ja) * 2018-07-11 2021-11-25 モメンタ ファーマシューティカルズ インコーポレイテッド ＣＴＬＡ−４を標的とする改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
AU2020348457A1 (en) 2019-09-19 2022-04-07 Leap Therapeutics, Inc. Use of DKK-1 inhibitors for treating cancer
WO2021102403A1 (en) 2019-11-22 2021-05-27 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors
KR102494042B1 (ko) * 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
CA3206789A1 (en) * 2021-02-05 2022-08-11 Gregory A. Demopulos Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
JP2024533439A (ja) 2021-09-10 2024-09-12 リープ セラピューティクス，インコーポレイテッド 併用療法
IL318268A (en) 2022-07-12 2025-03-01 Leap Therapeutics Inc Combined treatment
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0975755B2 (en) 1997-04-16 2011-08-03 Millennium Pharmaceuticals, Inc. Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
AU2001234944A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
CA2446582A1 (en) 2001-05-17 2002-11-21 Genome Therapeutics Corporation Reagents and methods for modulating dkk-mediated interactions
EP1461448A2 (en) 2001-11-07 2004-09-29 The Board Of Trustees Of The University Of Arkansas Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
US7308364B2 (en) 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
AU2004274861A1 (en) 2003-06-06 2005-03-31 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
US7709611B2 (en) 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
AU2008214344B2 (en) * 2007-02-08 2012-06-07 Merck Sharp & Dohme Corp. Antibodies specific for Dkk-1
AU2010245833B2 (en) * 2009-05-07 2014-03-27 Novartis Ag Compositions and methods of use for binding molecules to Dickkopf-1 or Dickkopf-4 or both

Also Published As

Publication number Publication date
HUE034625T2 (en) 2018-02-28
CA2758252A1 (en) 2010-10-14
AU2010234611A1 (en) 2011-10-20
KR20140033523A (ko) 2014-03-18
ME02798B (me) 2018-01-20
PL3514173T3 (pl) 2022-01-17
EP2417158A1 (en) 2012-02-15
US20100260754A1 (en) 2010-10-14
ME03378B (me) 2020-01-20
SI2930184T1 (sl) 2019-06-28
DK2417158T3 (en) 2017-10-16
AR075989A1 (es) 2011-05-11
SI2417158T1 (sl) 2017-10-30
TW201100101A (en) 2011-01-01
HUE043904T2 (hu) 2019-09-30
EP2930184A1 (en) 2015-10-14
LT2930184T (lt) 2019-05-10
US8148498B2 (en) 2012-04-03
ES2728911T3 (es) 2019-10-29
NZ595011A (en) 2013-05-31
KR20110124364A (ko) 2011-11-16
WO2010117980A1 (en) 2010-10-14
PT2930184T (pt) 2019-06-17
ES2644244T3 (es) 2017-11-28
CY1121637T1 (el) 2020-07-31
RS56505B1 (sr) 2018-02-28
DK2417158T4 (da) 2018-01-29
HRP20171400T1 (hr) 2017-11-03
IL214845A (en) 2016-06-30
EP2930184B1 (en) 2019-03-27
LT2417158T (lt) 2017-10-10
KR101461362B1 (ko) 2014-11-13
KR20140090273A (ko) 2014-07-16
JP5759977B2 (ja) 2015-08-05
PL2417158T3 (pl) 2017-12-29
PL2930184T3 (pl) 2019-10-31
TWI546079B (zh) 2016-08-21
DK3514173T3 (da) 2021-08-02
AU2010234611B2 (en) 2013-02-07
CN102388065A (zh) 2012-03-21
RS62214B1 (sr) 2021-09-30
RS58612B1 (sr) 2019-05-31
JP2012523417A (ja) 2012-10-04
SG175244A1 (en) 2011-12-29
ZA201107256B (en) 2013-03-27
LT3514173T (lt) 2021-09-10
EP2417158B9 (en) 2017-12-06
ES2887176T3 (es) 2021-12-22
HRP20190643T1 (hr) 2019-05-31
PT2417158T (pt) 2017-10-23
CY1124412T1 (el) 2022-07-22
EP3514173B8 (en) 2021-08-04
HUE055376T2 (hu) 2021-11-29
EA201171237A1 (ru) 2012-04-30
TR201907261T4 (tr) 2019-06-21
PT3514173T (pt) 2021-08-16
EA021401B1 (ru) 2015-06-30
MX2011010707A (es) 2012-02-28
EP2417158B1 (en) 2017-08-02
IL214845A0 (en) 2011-11-30
HRP20211343T1 (hr) 2021-11-26
BRPI1014157A2 (pt) 2020-09-29
EP3514173B1 (en) 2021-06-23
EP3514173A1 (en) 2019-07-24
DK2930184T3 (da) 2019-05-13
UA103916C2 (xx) 2013-12-10
CN102388065B (zh) 2014-09-03
CA2758252C (en) 2015-02-24
SI3514173T1 (sl) 2021-09-30
BRPI1014157B1 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
CY1119399T1 (el) Aντι-dkk-1 αντισωματα
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
CY1123883T1 (el) Ανθρωποποιημενα αντισωματα κατα της liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1125267T1 (el) Antiσωmata eiδiκως σynδeonta pd-1 kai xphσeiς aytωn
CY1124292T1 (el) Συνθεσεις για τροποποιηση της εκφρασης tau
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1122593T1 (el) Αντισωματα εναντι-cd40 και χρησεις αυτων
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1119154T1 (el) Anti-vla-4 αντισωματα
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
CY1120412T1 (el) Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31
CY1120556T1 (el) Δικυκλικα ετεροκυκλα ως αναστολεις fgfr
CY1119070T1 (el) Διαμορφωση της εκφρασης τρανσθυρετινης
CY1119567T1 (el) Θεραπευτικα πεπτιδια
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1118761T1 (el) Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3)
CY1118244T1 (el) Αντισωματα κατα της il-25
CY1118143T1 (el) Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
CY1117447T1 (el) Μια συνθεση που περιλαμβανει ενα αντιβιοτικο και ενα παραγοντα διασπορας
BR112014029883A2 (pt) anticorpo totalmente humano, fragmento fab de anticorpo, anticorpo humano de cadeia única e método para tratar um amplo espectro de cânceres.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
EA201791693A1 (ru) Гетеродимерные иммуноглобулины